The derived neutrophil‐to‐lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T‐cell lymphoma

Hong, Huangming; Fang, Xiaojie; Huang, He; Wang, Zhao; Lin, Tongyu; Yao, Herui

doi:10.1111/bjh.16447

Cited by 15 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, 71.4% of patients relapsed after autologous stem cell transplantation within 10 months. Honghuangming et al 19 reported a similar outcome in a retrospective study. Untreated AITL patients ( n = 59) who received cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone (CHOPE) showed an ORR of 60% (45% CR), which was not superior to that in the CHOP regimen group.…”

Section: Discussionmentioning

confidence: 64%

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

et al. 2022

View full text Add to dashboard Cite

Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma (PTCL) with a poor prognosis, and an effective first-line therapy is lacking.Chidamide is a selective histone deacetylase inhibitor and has been approved by the China Food and Drug Administration for relapsed or refractory PTCL. We conducted a multicenter phase II clinical trial combining chidamide with prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles in untreated AITL patients in China. The primary objectives were the overall response rate (ORR) and complete remission (CR) rate after eight cycles of the CPET regimen. The secondary endpoints were progression-free survival (PFS) and safety. Of the 71 enrolled patients, 51 completed the eight cycles of the CPET regimen. The ORR and CR of the 51 patients were 90.2 and 54.9%, respectively. After a median follow-up of 11.4 months (95% confidence interval[CI], 9.9-17.0), the median PFS of the 51 patients was 42.6 months (95% CI, 27.7-not reached) and the median overall survival (OS) was not reached. The 2-year PFS rate and OS rate were 66.5 and 82.2%, respectively. Sixty-eight patients received at least one cycle of CPET regimen and were included as the safety assessment population. The most common grade 3/4 adverse event was neutropenia (n = 22, 32.3%). Twelve patients showed treatment-related infections and recovered from antibiotic therapy; the other adverse events were mostly mild and reversible. The oral CPET regimen is an effective, tolerable, and economical choice for untreated AITL in a Chinese population. This trial was registered in www.clinicaltrials.gov as NCT03273452. | INTRODUCTIONAngioimmunoblastic T-cell lymphoma (AITL) is a mature T-cell lymphoma as defined by the World Health Organization (WHO) 2016 Classification. 1 Globally, AITL accounts for 1-2% of non-Hodgkin lymphomas and 15-20% of peripheral T-cell lymphoma (PTCL), and AITL is the second most common PTCL after PTCL not otherwise specified. 2 AITL accounted for 1.6% of non-Hodgkin lymphomas and

show abstract

Section: Discussionmentioning

confidence: 64%

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, LDH levels were included in the TNM staging system for melanoma [ 18 ]. In lymphoma [ 11 , 12 ], melanoma [ 19 ], lung cancer [ 20 ], penile cancer [ 21 ] and other solid tumors, increased LDH is shown to be an adverse factor for the survival of patients.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, inflammatory indicators are also believed to be related to the prognosis of various tumors. Several studies have used derived neutrophil-to-lymphocyte ratio (dNLR) as a prognostic indicator, and increased dNLR value is associated with poor prognosis of various malignant tumors including urothelial carcinoma [ 8 , 9 ], breast cancer [ 10 ] and lymphoma [ 11 , 12 ]. dNLR can reflect the immune state of the tumor microenvironment.…”

Section: Introductionmentioning

confidence: 99%

High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine

Lin

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Objective To investigate the prognostic value of derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) in patients with advanced HER2 positive breast cancer treated with trastuzumab emtansine. Methods Fifty one patients with advanced HER2 positive breast cancer who received T-DM1 treatment in Harbin Medical University Cancer Hospital were selected. The clinical data and blood test indexes were collected, and the ROC curve determined the optimal cut-off value. Kaplan-Meier survival curve and Cox regression model was used to analyze the effect of different levels of dNLR,LDH,LNI (dNLR combined with LDH index) before and after T-DM1 treatment on the survival of patients. Results The median PFS and OS of the patients with advanced HER2 positive breast cancer who received T-DM1 treatment were 6.9 months and 22.2 months, respectively. The optimal cut-off value of LDH and dNLR before T-DM1 treatment was 244 U / L (P = 0.003) and 1.985 (P = 0.013), respectively. Higher LDH and dNLR were significantly correlated with shorter median PFS and OS (P < 0.05). The median PFS of patients with LNI (0), LNI (1) and LNI (2) were 8.1 months, 5.5 months and 2.3 months, respectively, P = 0.007. Univariate and multivariate analysis showed that LDH > 244 U / L, dNLR > 1.985, LNI > 0, ECOG ≥1 and HER-2 (IHC2 +, FISH+) before the T-DM1 treatment were the poor prognostic factors. LDH uptrend after the T-DM1 treatment also predicted poor prognosis. Conclusion Serum LDH > 244 U / L and dNLR > 1.985 before the T-DM1 treatment were prognostic risk factors for patients with advanced HER2 positive breast cancer receiving T-DM1 treatment. The higher LNI score was significantly associated with shorter PFS and OS. LDH uptrend after T-DM1 treatment was also related to the poor prognosis.

show abstract

“…For years, cumulative studies have confirmed the predictive role of clinical variables on prognosis, remarkably immune and inflammatory response, which has been considered one of the main prognostic predictors in several solid tumors ( 6 – 9 ). Recently Qi et al.…”

Section: Introductionmentioning

confidence: 94%

External Application of a Nomogram to Predict Survival and Benefit of Peripheral Blood Inflammatory Indexes in Limited-Stage Small Cell Lung Cancer

Wei

Hou²,

Liu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundQi et al. recently proposed a nomogram to reveal the prognostic value of peripheral blood inflammatory indexes (named Risk) and predict overall survival (OS) in limited-stage small cell lung cancer (LS-SCLC). However, it hasn’t undergone external application so far. This study aimed to verify the role of Risk as a prognostic variable of OS and apply the nomogram externally.MethodsWe used a retrospective analysis of clinical data of 254 patients diagnosed as LS-SCLC in Shanxi Cancer Hospital from January 2015 to December 2018 to apply Qi’s nomogram externally. We also performed subgroup analysis to explore the predictive value of Risk. The model was evaluated in terms of discrimination (the area under the ROC curve (AUC ROC) and calibration (calibration plots).ResultsThe prognosis of patients with low-Risk was significantly better than those with high-Risk in our cohort (p<0.01). The AUC of 1-, 2-, and 3-year OS was 0.644, 0.666, and 0.635, respectively. The calibration curve showed a nearly ideal calibration-slope of 1-, 2-, and 3-year OS (1.00 (0.41-1.59), 1.00 (0.54-1.46) and 1.00 (0.43-1.57), respectively).ConclusionThe external application of nomogram added Risk for predicting OS in LS-SCLC patients showed a moderate-to-good performance using a cohort with different case-mix characteristics. The external application confirmed the predictive value of Risk and the usefulness of the nomogram for the prediction of OS.

show abstract

The derived neutrophil‐to‐lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T‐cell lymphoma

Cited by 15 publications

References 15 publications

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine

External Application of a Nomogram to Predict Survival and Benefit of Peripheral Blood Inflammatory Indexes in Limited-Stage Small Cell Lung Cancer

Contact Info

Product

Resources

About